Madrigal Pharmaceuticals, Inc.
MDGL
#1701
Rank
$12.450 B
Marketcap
United States
Country
$538.88
Share price
0.67%
Change (1 day)
20.27%
Change (1 year)
Categories
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Key Metrics
Trailing P/E
—
Forward P/E
55.52
EPS (TTM)
$-14.12
Forward EPS
$9.63
Price / Book
23.56
EV / EBITDA
-36.9x
Beta
-0.99
Dividend Yield
—
Return on Equity
-53.31%
Return on Assets
-17.84%
Debt / Equity
66.40
Current Ratio
3.21
Gross Margin
91.48%
Operating Margin
-15.46%
Net Profit Margin
-25.32%
Free Cash Flow
$-80,466,248
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 19 – Sep 17
-1.07%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$958.403M
Latest Net Income$-288,284,000
Reporting periods2
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Madrigal Pharmaceuticals, Inc. with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
MDGL
No recent news available. Set FINNHUB_API_KEY to enable news.
